| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Afya Limited (NASDAQ:AFYA, B3: A2FY34)) ("Afya" or the "Company"), the leading medical education group and medi...
UBS analyst Andre Salles upgrades Afya (NASDAQ:AFYA) from Neutral to Buy and lowers the price target from $19.5 to $19.
JP Morgan analyst Marcelo Santos upgrades Afya (NASDAQ:AFYA) from Neutral to Overweight and raises the price target from $23...
Afya (NASDAQ:AFYA) reported quarterly earnings of $0.40 per share which beat the analyst consensus estimate of $0.38 by 5.53 pe...
AFYA LIMITED ANNOUNCES A NEW SHARE REPURCHASE PROGRAM Belo Horizonte, Brazil, August 13, 2025 – Afya Limited (NASDAQ:AFYA, B3: ...